Cited by 667Cancer Genomics and DiagnosticsRenal cell carcinoma treatmentChromatin Remodeling and Cancer

Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor

Open access
Xu, Xun, Hou, Yong, Yin, Xuyang, Bao, Li, Tang, Aifa, Song, Luting, Li, Fuqiang, Tsang, Shirley +31 more·2012·Cell

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer and has very few mutations that are shared between different patients. To better understand the intratumoral genetics underlying mutations of ccRCC, we carried out single-cell exome sequencing on a ccRCC tumor and its adjacent kidney tissue. Our data indicate that this tumor was unlikely to have resulted from mutations in VHL and PBRM1. Quantitative population genetic analysis indicates that the tumor did not contain any significant clonal subpopulations and also showed that mutations that had different allele frequencies within the population also had different mutation spectrums. Analyses of these data allowed us to delineate a detailed intratumoral genetic landscape at a single-cell level. Our pilot study demonstrates that ccRCC may be more genetically complex than previously thought and provides information that can lead to new ways to investigate individual tumors, with the aim of developing more effective cellular targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2012.02.025

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rapid technological advances have enabled genome-wide profiling of RNA, DNA, protein, epigenetic modifications, chromatin accessibility, and other molecular events in single cells.

    “rapid technological advances have enabled genome-wide profiling of RNA7–10, DNA11–17, protein18–21, epigenetic modifications22–26, chromatin accessibility27,28, and other molecular events29 in single cells.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., Li, F., Tsang, S., Wu, K., Wu, H., He, W., Zeng, L., Xing, M., Wu, R., Jiang, H., Liu, X., Cao, D., Guo, G., Hu, X., Gui, Y., Li, Z., Xie, W., Sun, X., Shi, M., Cai, Z., Wang, B., Zhong, M., Li, J., Lu, Z., Gu, N., Zhang, X., Goodman, L., Bolund, L., Wang, J., Yang, H., Kristiansen, K., Dean, M., Li, Y., & Wang, J.
Affiliations
  • BGI Group (China) (CN)
  • Shenzhen University (CN)
  • Peking University Shenzhen Hospital (CN)
  • State Key Laboratory of Digital Medical Engineering (CN)
Corresponding author
  • Dean, Michael
  • Li, Yingrui
  • Wang, Jun
Venue
Cell
Publisher
Elsevier BV
Published
2012-03
Volume
148
Issue
5
Pages
886-895
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2009569945
Cited by
667
References
56
Citations by year
2026: 4 · 2025: 15 · 2024: 15 · 2023: 26 · 2022: 49 · 2021: 31 · 2020: 42 · 2019: 41 · 2018: 61 · 2017: 58 · 2016: 50 · 2015: 56 · 2014: 79 · 2013: 86 · 2012: 53
FWCI
28.90
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Alcohol Abuse and Alcoholism (R21AA022707)
  • National Cancer Institute (ZIABC011301, ZIABC011300)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
clear cell renal cell carcinoma, intratumoral heterogeneity, point mutations, clonal subpopulations, VHL, PBRM1, allele frequency, tumor evolution, targeted therapy
MeSH terms
Carcinoma, Renal Cell, DNA-Binding Proteins, Gene Frequency, Humans, Kidney Neoplasms, Male, Middle Aged, Mutation, Nuclear Proteins, Phylogeny, Pilot Projects, Transcription Factors, Principal Component Analysis, Von Hippel-Lindau Tumor Suppressor Protein, Single-Cell Analysis, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review